The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure

Clinical and Experimental Nephrology

Volumn 17, Issue 6, 2013, Pages 834-838

  Otsuka, Tomoyuki ^a   Sakai, Yukinao ^a   Ohno, Dai ^a   Murasawa, Tsuneo ^a   Sato, Naoki ^a   Tsuruoka, Shuichi ^b  

^a NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Chronic kidney disease; Congestive heart failure; Diuretic; Renoprotection; Tolvaptan

Indexed keywords

CREATININE; TOLVAPTAN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DIURETIC THERAPY; DRUG DOSE INCREASE; FEMALE; FREE WATER CLEARANCE; HUMAN; HYPERNATREMIA; KIDNEY FUNCTION; LOADING DRUG DOSE; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SERUM OSMOLALITY; URINE OSMOLALITY; URINE VOLUME;

AGED; BENZAZEPINES; CREATININE; DIURETICS; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 84891486574     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-013-0788-6     Document Type: Article

References (14)

1. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860-7. http://www.ncbi.nlm.nih.gov/pubmed/9864265.
2. Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288-94. http://www.ncbi.nlm.nih.gov/pubmed/10604960.
3. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690-6. http://www.ncbi.nlm.nih.gov/pubmed/12742979.
4. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA. 2004;291:1963-71.
5. Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to Evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail. 2005;11:260-9.
6. Blair JEA, Pang PS, Schrier RW, et al. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011;32:2563-72.
7. Vaduganathan M, Gheorghiade M, Pang PS, et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. J Cardiovasc Med (Hagerstown). 2012;13:415-22. http://www.ncbi.nlm.nih.gov/pubmed/ 22673023.
8. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273-8.
9. Okada T, Sakaguchi T, Hatamura I, et al. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. Clin Exp Nephrol. 2009;13:438-46. http://www.ncbi.nlm.nih.gov/pubmed/19452240.
10. Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther. 2011;25 Suppl 1:S67-76. http://www.ncbi.nlm.nih.gov/pubmed/22120095.
11. Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol. 2012. http://www.ncbi.nlm.nih.gov/pubmed/ 23159210.
12. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-96. http://www.ncbi.nlm.nih.gov/pubmed/19215833.
13. Peacock WF, Costanzo MR, De Marco T, et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology. 2009;113:12-9. http://www.ncbi.nlm.nih.gov/pubmed/18931492.
14. Bankir L, Bouby N. Vasopressin and urinary concentration: additional risk factors in the progression of chronic renal failure. Am J Kidney Dis. 1991;17:20-6. http://www.ncbi.nlm.nih.gov/pubmed/2024668.